Romanian Society of Pharmaceutical Sciences

« Back to Farmacia Journal 4/2023

PROTECTIVE EFFECTS OF ULTRASOUND-BASED PREOPERATIVE EXOGENOUS SACUBITRIL/VALSARTAN ON THE HEART AND KIDNEY OF PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION

YUNFEI WANG 1, LINA SUN 2, JING YU 1, YE ZHENG 1, YAHUAN HAO 1, YANJIE SU 1, LIQIU YAN1*

1Department of Cardiovascular Medicine, Cangzhou Central Hospital, Cangzhou, 061000, Hebei, China
2Second Department of Nephrology, Department of cardiovascular medicine, Cangzhou Central Hospital, Cangzhou, 061000, Hebei, China

Download Full Article PDF

This research aimed to demonstrate the protective effects of exogenous sacubitril/valsartan on the heart and kidney of patients undergoing percutaneous coronary intervention (PCI) preoperatively based on ultrasound. Three hundred patients undergoing PCI in our hospital were assigned to a control (Ctrl) group (150 patients receiving valsartan preoperatively) and a research (Res) group (150 patients receiving sacubitril/valsartan preoperatively). The myocardial injury, cardiac function (CF), renal function (RF) and complications of the two groups were compared preoperatively and postoperatively. The results showed that the troponin I (cTnI) and creatine kinase isoenzyme myocardial bands (CK-MB) in the two groups showed a decreasing trend postoperatively, and that of the Res group was more significant (p < 0.05). Postoperatively, the left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV) of the two groups of patients decreased, being more significant in the Res group (p < 0.05). Postoperatively, blood urea nitrogen (BUN) and creatinine (Cr) in the two groups were decreased, the trend being more evident in the Res group (p < 0.05). The drug efficiency in the Ctrl group and Res group was 84.67% and 93.33%, respectively, and the effective rate of drugs in the Res group was y higher (p < 0.05). In summary, ultrasonography had a positive adoption value in evaluating the treatment effect of coronary intervention, and exogenous sacubitril/valsartan had an important protective effect on the heart and kidneys of patients undergoing PCI.